Bavarian Nordic
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
July 25, 2023Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
Bavarian Nordic seals $539 million vaccine deal
October 3, 2017Manufacturing and Production BARDA, Bavarian Nordic, biotech, drugs, pharma, pharmaceutical
Bavarian Nordic, a Danish biotech, has continued its partnership with the US government by agreeing a $539 million deal to …
Janssen and Bavarian Nordic to collaborate on HPV vaccine
December 23, 2015Research and Development Bavarian Nordic, HPV, Janssen, Vaccine, human papillomavirus, prime boost
Janssen has announced a new collaboration and license agreement with Bavarian Nordic to develop a vaccine for chronic Human Papillomavirus …
Bavarian Nordic courting cancer vaccine backers
November 12, 2010Research and Development, Sales and Marketing Bavarian Nordic, Dendreon, Prostvac, Provenge, TroVax, cancer vaccine, prostate cancer, prostate cancer vaccine, zibotentan
Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
